NASDAQ$CARM

Carisma Therapeutics Inc · Q4 2014 earnings

Q4 2014 earnings · · Investor relations

Headline financials

Total Revenue

$375K

Previous: $510K-26.5%
EPS (adj)

-$2.37

Previous: -$293.20+99.2%
Net Income

-$8.28M

Previous: -$5.96M-38.9%
Operating Income

-$8M

Previous: -$4.17M-91.8%
Gross Profit

$375K

Previous: $510K-26.5%
Cash & Equivalents

$54.1M

No prior period
Total Assets

$55M

No prior period
Stock-Based Comp

$487K

No prior period

Revenue & EPS history

Carisma Therapeutics · Revenue · Quarterly

$375K

Q4 2014-26.5%vs Q4 2013
Beat estimate in 7 of 8 quarters(88%)
ActualEstimate

Revenue by segment

Carisma Therapeutics · $19.6M total across 1 segment · Q4 2024

  • Collaboration Revenues
    $19.6M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports

Historical avg

+0.9%

Avg return

Earnings day

+0.6%

Avg return

5 days after

+6.2%

Avg return

30 days after

54%

26 / 48 earnings

Positive

+32.8%

Q2 2016

Best reaction

-29.2%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+6.2%+10.1%-98.0%
Q3 2025+2.4%+27.8%+22.6%
Q2 2025-11.8%-8.6%+31.7%
Q1 2025+3.1%-1.4%+153.1%
Q4 2024+11.5%+5.7%-5.6%
Q3 2024-9.0%-10.4%-28.0%
Q2 2024+10.7%+26.2%+25.0%
Q1 2024-4.5%-5.8%-30.3%
Q4 2023-11.5%-19.8%-28.2%
Q3 2023-19.5%-11.1%-15.4%
Q2 2023+12.9%+22.4%-12.9%
Q1 2023-12.3%-17.7%+4.1%
Q4 2022+1.2%-9.6%+62.9%
Q3 2022+0.5%
Q2 2022-3.6%
Q1 2022-1.3%
Q4 2021-2.5%
Q3 2021+3.4%
Q2 2021-8.8%
Q1 2021+5.4%
Q4 2020+5.6%
Q3 2020+3.9%
Q2 2020+7.0%
Q1 2020+1.6%
Q4 2019-29.2%
Q3 2019+0.9%
Q2 2019+1.7%
Q1 2019-2.9%
Q4 2018+0.0%
Q3 2018-7.0%
Q2 2018+2.1%
Q1 2018+17.1%
Q4 2017+19.0%
Q3 2017+2.8%
Q2 2017-12.4%
Q1 2017-2.7%
Q4 2016+13.7%
Q3 2016-4.2%
Q2 2016+32.8%
Q1 2016+6.1%
Q4 2015-8.6%
Q3 2015-0.7%
Q2 2015+15.2%
Q1 2015+17.9%
Q4 2014-2.4%
Q3 2014-2.1%
Q2 2014-3.9%
Q1 2014+1.1%
Q4 2013
Q3 2013
Q2 2013
Q1 2013
Q4 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro